11C-Dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls

Journal of Nuclear Medicine

Volumn 50, Issue 3, 2009, Pages 382-389

  Goland, Robin ^a   Freeby, Matthew ^a   Parsey, Ramin ^a   Saisho, Yoshifumi ^b   Kumar, Dileep ^a   Simpson, Norman ^a   Hirsch, Joy ^a   Prince, Martin ^a   Maffei, Antonella ^a,c   John Mann, J ^a   Butler, Peter C ^b   Van Heertum, Ronald ^a   Leibel, Rudolph L ^a   Ichise, Masanori ^a   Harris, Paul E ^a  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

cell mass; 11C dihydrotetra benazine; Diabetes; PET; VMAT2

Indexed keywords

BIOLOGICAL MARKER; CARBON 11; DIHYDROTETRABENAZINE; DIHYDROTETRABENAZINE C 11; INSULIN; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2; CARBON; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SLC18A2 PROTEIN, HUMAN; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORTER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; KIDNEY CORTEX; MALE; MOLECULAR IMAGING; PANCREAS; PANCREAS ISLET BETA CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; METABOLISM; REFERENCE VALUE; SCINTISCANNING;

ADULT; CARBON RADIOISOTOPES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INSULIN-SECRETING CELLS; KIDNEY CORTEX; MALE; PANCREAS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; REFERENCE VALUES; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 62449183526     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.054866     Document Type: Article

References (32)

1. Kloppel G, Drenck CR, Oberholzer M, Heitz PU. Morphometric evidence for a striking B-cell reduction at the clinical onset of type 1 diabetes. Virchows Arch. 1984:403:441-452.
2. Butler AE, Galasso R, Meier JJ, Basu R. Rizza RA. Butler PC. Modestly-increased beta cell apoptosis but no increased beta cell replication in recent- onset type 1 diabetic patients who died of diabetic ketoacidosis. Diabetologia. 2007;50:2323-2331.
3. McCulloch DK, Koerker DJ, Kahn SE, Bonner-Weir S, Palmer J P. Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in slreptozocin-administered baboons. Diabetes. 1991;40:673-679.
4. Dotta F, Censini S, van Halteren AG, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci USA. 2007:104:5115-5120.
5. Wajchenberg BL. B-Cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28:187-218.
6. Tsai EB, Sherry NA, Palmer JP, Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia. 2006;49:261-270.
7. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004;53(suppl 3):S 16-S21.
8. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharm. 1995;294:577-583.
9. Anlauf M, Eissele R, Schafer MK. et al. Expression of the two isoforms of the vesicular monoamine transporter (VM AT 1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem. 2003;51:1027-1040.
10. Maffei A, Liu Z, Wilkowski P. et al. Identification of tissue-restricted transcripts in human islets. Endocrinology. 2004;145:4513-4521.
11. Raffo A, Hancock K. Polito T, et al. Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine. J Endocrinol. 2008;198:41-49.
12. Erickson JD, Schafer MK, Bonner TI, Eiden LE. Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA, 1996;93:5166-5171.
13. 3H] dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J Neurochem. 1988;50: 1131-1136.
14. 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med. 2008;49:1171-1176.
15. 11C]telrabenazine to vesicular monoamine transporters in mouse brain. Life Sci. 1992;51:593-600.
16. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. 2006;26:1 198-1212.
17. 11C]DTBZ. Nucl Med Biol. 2006;33:855-864.
18. Kilbourn M, Lee L, Vander Borght T, Jewett D, Frey K. Binding of alpha-dihydroletrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharm. 1995;278:249-252.
19. 11C-DASB and PET in humans. J Nucl Med. 2006;47:1796-1802.
20. 11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J Cereb Blood Flow Metab. 1996;16:1288-1299.
21. Pick A, Clark J, Kubstrup C, et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes. 1998;47:358-364.
22. 11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23:1096- 1112.
23. 18F]FP-TZTP. J Cereb Blood Flow Metab. 2008;28:420-430.
24. 11CJDASB: test-retest reproducibility using a multilinear reference tissue parametric imaging method. J Nucl Med. 2006;47:208-214.
25. Kim J, Cai W, Feng D, Eberl S. Segmentation of VOI from multidimensional dynamic PET images by integrating spatial and temporal features. IEEE Trans Inf Technol Biomed. 2006;10:637-646.
26. Mehvar R, Jamali F, Watson MW. Skelton D. Pharmacokinetics of letrabenazine and its major metabolite in man and rat: bioavailability and dose dependency studies. Drug Metab Dispos. 1987;15:250-255.
27. Meier JJ, Bhushan A, Butler AE. Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence lor islet regeneration? Diabetologia. 2005;48:2221-2228.
28. 18F-desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression. J Nucl Med. 2003;44:1700-1706.
29. Jagoda EM. Vaquero JJ. Seidel J, Green MV. Eckelman WC. Experiment assessment of mass effects in the rat: implications for smalt animal PET imaging. Nucl Med Biol. 2004;31:771-779.
30. Williams AJ, Chau W, Callaway MP, Dayan CM. Magnetic resonance imaging: a reliable method for measuring pancreatic volume in type 1 diabetes. Diabet Med. 2007;24:35-40.
31. Nyren S, Blomqvist L, Efendic S, Grill V. Pancreas size and insulin secretion: lack of association in non-diabetic subjects. Acta Diabelol. 1996;33:274-276.
32. Meier JJ, Butler AE, Saisho Y, et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes. 2008;57:1584-1594.